CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 301 enrolled
Drug / intervention
SER120 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00937859
NCT00937859Phase 3Completed
CompareCT.gov

A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia

Serenity Pharmaceuticals, Inc.·interventional·Posted Jul 13, 2009·Updated Sep 18, 2020

In Brief

A Phase 3 clinical trial evaluating SER120 and Placebo for Nocturia. Completed, enrolled 301 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2009
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.0 years ago

Interventions

SER120drug

SER120

Placebodrug

Placebo